Do Outcomes in Mohs Surgery Differ by Surgeon Gender—And Does It Matter?

There is a quiet truth in surgery that patients feel, even if they cannot always name it.

Outcomes are not just about what was removed. They are about how care was delivered.

A large population-based study examining over 100,000 surgical patients found that those treated by female surgeons had a small but statistically significant reduction in 30-day mortality, with similar complication and readmission rates compared to male surgeons. The difference is not dramatic—but it is consistent, and it is real.

So what does that mean in a setting like dermatologic surgery, where mortality is not the endpoint?

It means we shift the lens.

In Mohs micrographic surgery, the outcomes that matter most are cure, complication rate, pain experience, and cosmetic result.

And here is where the conversation becomes more interesting.

Mohs surgery is already one of the most precise procedures in medicine. It offers complete margin control, high cure rates, and maximal tissue preservation—all in an outpatient setting 1. Complication rates are low, with adverse events occurring in well under 1% of cases, and serious events are exceedingly rare 2.

Pain is typically minimal to moderate and short-lived, often resolving within days and manageable with simple measures 3.

Cosmetic outcomes are directly tied to surgical judgment: how much tissue is removed, how the wound is reconstructed, and how well healing is guided over time.

This is where surgical style matters.

The literature suggests that female physicians, across specialties, are more likely to follow evidence-based guidelines, communicate clearly, and take a more patient-centered approach to care. These are not abstract qualities. In surgery, they translate into decisions.

• When to take another margin versus when to stop
• How aggressively to reconstruct versus when to preserve
• How carefully to plan closure for long-term cosmesis
• How clearly expectations are set before the first incision

In Mohs surgery, cure is binary—you either clear the tumor or you do not. But everything else exists on a spectrum.

A slightly smaller defect.
A more thoughtful closure.
A patient who understands what to expect.
A wound that heals without complication.

These are incremental differences, but they compound.

The data from general surgery showing lower mortality with female surgeons likely reflects not a single factor, but a pattern: attention to detail, adherence to process, communication, and risk calibration.

When you translate that into outpatient dermatologic surgery, the equivalent endpoints are not life or death—they are experience and outcome.

• Lower likelihood of avoidable complications
• Better alignment between expectation and result
• Thoughtful reconstruction that prioritizes both function and appearance
• A patient who feels seen, informed, and steady throughout the process

And importantly, Mohs surgery is not just technical—it is interpretive. The surgeon is both surgeon and pathologist, making real-time decisions that directly shape the final defect and reconstruction.

Precision is not just in the blade. It is in judgment.

For patients, this means something simple: the person performing your surgery matters—not just in training, but in how they practice.

For clinicians, it raises a more important question: what aspects of care lead to better outcomes, and how do we standardize them across all surgeons?

Because the goal is not comparison.

The goal is improvement.

In the end, the best surgical outcome is not just a cured cancer.

It is a patient who heals well, feels well, and looks in the mirror months later without being reminded of the day they had surgery.

That is where surgical skill, judgment, and human care intersect—and where the smallest differences quietly matter most.